Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $27.6667.

ZVRA has been the subject of a number of research reports. Weiss Ratings cut shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Guggenheim raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Canaccord Genuity Group raised their price target on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating on shares of Zevra Therapeutics in a report on Tuesday. Finally, Citizens Jmp lifted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday.

Zevra Therapeutics Trading Up 13.0%

NASDAQ:ZVRA opened at $13.66 on Friday. The stock has a market capitalization of $807.58 million, a price-to-earnings ratio of 6.86 and a beta of 0.91. The firm has a fifty day simple moving average of $10.46 and a two-hundred day simple moving average of $9.42. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $13.80.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The business had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. Equities analysts predict that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics during the fourth quarter valued at about $53,000. Russell Investments Group Ltd. grew its holdings in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics during the second quarter valued at about $92,000. Finally, Quarry LP acquired a new position in shares of Zevra Therapeutics during the third quarter valued at about $103,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics News Summary

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Zevra announced Orange Book listing for a U.S. patent tied to MIPLYFFA, reinforcing exclusivity for the company’s only approved drug and potentially extending protection to 2041. Article Title
• Positive Sentiment: BTIG reaffirmed its buy rating and raised its price target to $27 from $23, signaling confidence in Zevra’s growth and valuation.
• Positive Sentiment: Citizens JMP increased its target to $25 from $18 and maintained an outperform rating, adding to bullish analyst momentum.
• Positive Sentiment: Cantor Fitzgerald lifted its target to $34 from $24 with an overweight rating, reinforcing the view that the stock still has substantial upside.
• Positive Sentiment: Unusually heavy call buying points to rising speculative interest in further gains for ZVRA.
• Neutral Sentiment: Short-interest data showed no meaningful change in shares reported short, so it does not appear to be a major driver today.
• Neutral Sentiment: A follow-up article questioned whether Zevra is using MIPLYFFA patent extensions to deepen its rare-disease moat, reflecting investor focus on the exclusivity story. Article Title

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.